Third-Line Therapy Shows Limited Efficacy in Real-World aGVHD Population | CancerNetwork The real-world CHRONOS study may set a new benchmark for the third-line management of acute graft-versus-host-disease with gastrointestinal involvement.

📰 #Media – We’re pleased to share that the real‑world CHRONOS study, the largest evaluation to date of third‑line therapy in GI-aGVHD, has just been featured in CancerNetwork.

👉 Read the article here: www.cancernetwork.com/view/third-l...

#Microbiome #Microbiotherapy #aGvHD #Hematology #Oncology

📰 #Media – Proud to be featured in Targeted Oncology highlighting the final Phase 3 ARES results of MaaT013, presented yesterday at EBMT by Prof. Florent Malard.

👉 Read the full article: www.targetedonc.com/view/microbi...

@theebmt.bsky.social
#Microbiome #Microbiotherapy #aGvHD #Hematology